MiNK Therapeutics (INKT) EBITDA (2020 - 2026)
MiNK Therapeutics (INKT) posted EBITDA of -$2.9 million for Q1 2026, down 6.52% sequentially from -$2.7 million in Q4 2025, and down 6.71% YoY from -$3.1 million in Q1 2025.
MiNK Therapeutics (INKT) EBITDA (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported EBITDA for 7 years, with the latest figure at -$2.9 million in Q1 2026.
- Quarterly EBITDA fell 6.71% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.8 million (down 26.23% YoY) and the FY2025 annual result came in at -$12.6 million, down 12.0% from the prior year.
- EBITDA eased to -$2.9 million in Q1 2026 per INKT's latest filing, from -$2.7 million in the prior quarter.
- Over five years, EBITDA peaked at -$1.9 million in Q3 2024 and troughed at -$8.0 million in Q3 2022.
- A 5-year average of -$4.7 million and a median of -$4.1 million in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2024: EBITDA sank 145.14% in 2022, then soared 63.91% in 2024.
- Over 5 years, EBITDA stood at -$7.9 million in 2022, then surged by 30.28% to -$5.5 million in 2023, then jumped by 54.51% to -$2.5 million in 2024, then fell by 8.13% to -$2.7 million in 2025, then fell by 6.52% to -$2.9 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$2.9 million, -$2.7 million, and -$3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | MiNK Therapeutics | 57.77 Mn | 57.77 Mn | - | -3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.22 Mn |
| Mar 31, 2026 | -2.88 Mn |
| Dec 31, 2025 | -2.71 Mn |
| Sep 30, 2025 | -3.18 Mn |
| Jun 30, 2025 | -4.05 Mn |
| Mar 31, 2025 | -2.70 Mn |
| Dec 31, 2024 | -2.50 Mn |
| Sep 30, 2024 | -1.89 Mn |
| Jun 30, 2024 | -3.07 Mn |
| Mar 31, 2024 | -3.83 Mn |
| Dec 31, 2023 | -5.50 Mn |
| Sep 30, 2023 | -5.22 Mn |
| Jun 30, 2023 | -6.34 Mn |
| Mar 31, 2023 | -5.85 Mn |
| Dec 31, 2022 | -7.89 Mn |
| Sep 30, 2022 | -7.99 Mn |
| Jun 30, 2022 | -7.70 Mn |
| Mar 31, 2022 | -7.37 Mn |
| Dec 31, 2021 | -6.36 Mn |
| Sep 30, 2021 | -13.38 Mn |